Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients.
Artif Organs
; 47(12): 1885-1892, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-37476931
ABSTRACT
BACKGROUND:
Assessing the outcome of Veno-Venous Extracorporeal Membrane Oxygenation (V-V ECMO) support remains challenging as plasma lactate (pLA), the widely used tool for this purpose, has been shown unreliable. We hypothesized that plasma oncostatin M (pOSM), a sensitive marker of leukocyte activation in infection and inflammation, could address this deficiency.METHODS:
Plasma OSM levels were measured by ELISA in 30 Acute Respiratory Distress Syndrome (ARDS) patients, prior to cannulation (baseline) and decannulation.RESULTS:
Based on the absolute pOSM levels at presentation, patients were separated into two groups, A and B. Patients in group A had low pOSM levels (Mean ± SD; Median, 1.1 ± 3.8; 0 pg/mL), whereas group B had high pOSM levels (1548 ± 1999; 767 pg/mL) [t-test p < 0.01]. The percentage of pOSM levels at decannulation relative to baseline OSM levels was significantly higher in those who died (116.8 ± 68.0; 85.3%) than those who survived (47.6 ± 25.5; 48.9%) [t-test p = 0.02; Mann-Whitney U Test p = 0.01]. Conversely, no significant difference was observed in the percentage of pLA levels between those who died (142.9 ± 179.9; 89.8%) and those who survived (79.3 ± 34.3; 81.8%) [t-test p = 0.31; Mann-Whitney U Test p = 0.63].CONCLUSION:
These early findings suggested critical value of absolute and relative pOSM to characterize the inflammatory burden of ARDS patients and the outcome of their V-V ECMO support.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Síndrome de Dificultad Respiratoria
/
Oxigenación por Membrana Extracorpórea
Límite:
Humans
Idioma:
En
Revista:
Artif Organs
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos